RecruitingNCT06899594
Psilocybin for methamphetamine use: feasibility and tolerability
About this title
Read the official source — NCT06899594Medication studyAges 25–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 25 years to 65 years.
- Listed locations
- ShreveportSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 4, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 20
- Sponsor
- Kevin Murnane
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 25 Years to 65 Years
- Official registry ID
- NCT06899594
- Official title
Show the full official title
A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Shreveport
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Kevin Murnane.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin 25 mg.
Who can participate?
Listed age limits: 25 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
